Drugs.com - New Drug Approvals

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

PRINCETON, N.J.--(BUSINESS WIRE) April 11, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a first-line treatment for adult...

Apr 26, 2025 - 14:23
 0
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 11, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a first-line treatment for adult...
Read More

Tags:

Previous Article

Neurelis Announces FDA Approval for Immediate Use Seizure Medication Valtoco (di...

Next Article

U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatri...

Related Posts

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

FDA Approves Tremfya (guselkumab) for Adult Patients wi...

Apr 26, 2025  0

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease

Uplizna (inebilizumab-cdon) is Now the First and Only F...

Apr 26, 2025  0

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

Novartis Receives Third FDA Approval for Oral Fabhalta ...

Apr 26, 2025  0